Prestige BioPharma is VC-Backed and has raised funding across M&A - KOREA SECURITIES DEPOSITORY and Series B rounds. It is backed by Korea Securities Depository and Dawnbright & Company.
Alternatives.pe tracks Prestige BioPharma's funding history, valuation trends, ownership structure, and transaction activity over time.
Last Updated: 2026-07-21
Browse all uploaded documents here
Extracted Financial Statement 2024
Extracted Financial Statement
ViewExtracted Financial Statement 2023
Extracted Financial Statement
ViewExplore the latest updates and insights
Prestige Biopharma to raise up to 490.9 billion won in IPO on Kospi with Samsung Securities as underwriter
Public Company
A view of the number of employees over time
Extracted Financial Statement 2022
Extracted Financial Statement
ViewExtracted Financial Statement 2021
Extracted Financial Statement
ViewConvertible Loan event
Prestige BioPharma Completes USD4M Drawdown of Convertible Loan for Series C Funding
Prestige BioPharma's USD25M Convertible Loan Converted to Shares by Octava
Key members of the management team